---
title: "The combination of new vaccines and drugs significantly reduces the risk of recurrence of melanoma."
description: "The combination of new vaccines and drugs significantly reduces the risk of recurrence of melanoma."
---


# The combination of new vaccines and drugs significantly reduces the risk of recurrence of melanoma.

import Tabs from '@theme/Tabs';
import TabItem from '@theme/TabItem';

<Tabs
	defaultValue="summary"
	values={[
	{label: 'summary', value: 'summary'},
	{label: 'score', value: 'score'},
]}>
<TabItem value="summary">
<img
  src="https://image.informedainews.com/2024/06/Hea-Omn-1717551888-0.jpg"
  alt="The combination of new vaccines and drugs significantly reduces the risk of recurrence of melanoma."
/>

<img
  src="https://image.informedainews.com/2024/06/Hea-86F-1717551888-1.jpg"
  alt="The combination of new vaccines and drugs significantly reduces the risk of recurrence of melanoma."
/>



New Vaccine and Drug Combination Reduces Melanoma Recurrence Risk

A combination therapy involving a new melanoma vaccine and existing anticancer drugs has reduced the risk of melanoma recurrence by 49% and the risk of spreading by 62% during a three-year trial. This combination therapy, consisting of Moderna's mRNA-4157 vaccine and Merck's Keytruda, is specifically targeted at high-risk melanoma patients who have undergone surgical removal of their tumors.

**Mechanism of Vaccine and Drug**

The mRNA-4157 vaccine is a personalized neoantigen therapy that leverages the unique DNA characteristics of a patient's tumor to stimulate an anticancer immune response. Keytruda blocks the PD-1 pathway in cancer cells, aiding the immune system in identifying and attacking these cells.

**Trial Results and Future Outlook**

After nearly three years of follow-up, the combined treatment has shown significant improvements in survival rates. Merck and Moderna have initiated Phase III clinical trials to further evaluate the efficacy of this combination therapy in melanoma and non-small cell lung cancer patients. Additionally, Phase II trials for renal cell carcinoma and bladder cancer have also commenced.

**Personal Insight**

This groundbreaking development not only brings new hope to melanoma patients but also demonstrates the immense potential of personalized medicine. With the accumulation of more clinical data, this combination therapy is poised to become a significant milestone in anticancer treatments.
</TabItem>
<TabItem value="score">
	| Scores     | Value   | Explanation |
	| -------- | ------- | ------- |
	| Objectivity  | 5    | 内容基于临床试验数据，较为客观地报道了研究成果。    |
	| Social Impact | 4     | 内容可能引发对癌症治疗新方法的关注和讨论。    |
	| Credibility    | 5    | 基于权威公司的临床试验数据，具有较高的可信度。    |
	| Potential    | 5    | 研究结果对癌症治疗领域具有重要影响，有望改善患者生存率。    |
	| Practicality    | 4    | 研究结果具有一定的实际应用前景，但需进一步临床验证。    |
	| Entertainment Value    | 2    | 内容偏向专业和科学，娱乐性较低。    |
</TabItem>
</Tabs>

[Full article>>](https://www.cnbeta.com.tw/articles/science/1433519.htm)
